Verastem gains $32M to target cancer stem cells
This article was originally published in Scrip
Verastem, a Cambridge, Massachusetts-based company, has set its sights on one of the hot areas of cancer biology – a subset of cells in cancers that appear resistant to conventional therapies. It has raised $32 million in a Series B round of financing to fund its work developing drugs to treat breast cancer and other cancers by selectively targeting cancer stem cells. The firm hopes to have its first candidate in the clinic in 2012.